[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elderly-people\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elderly-people":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,73,95,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":39,"locationsCount":4},"100594886","the-effects-of-cognitive-motor-dual-task-intervention-on-fall-prevention-among-older-adults-100594886",false,"NCT07025278","The Effects of Cognitive-motor Dual-task Intervention on Fall Prevention Among Older Adults","The Effects and Mechanisms of Game-based Cognitive-motor Dual-task Intervention on Fall Prevention Among Older Adults","Inclusion Criteria:\n\n1. Age ≥ 65 years old;\n2. Able to walk independently for at least 10 meters without obvious pain or difficulty;\n3. Free from lower limb and foot deformities, wounds, ulcers, or other diseases, and capable of wearing flexible devices;\n4. Scored as low or moderate fall risk on the Morse Fall Risk Assessment Scale;\n5. Scored \\> 40 points on the Berg Balance Scale and \\\u003C 20 seconds on the Time Up and Go Test (TUG);\n6. Scored ≥ 21 points on the Mini-Mental State Examination (MMSE);\n7. With an educational level of primary school or above, able to correctly understand instructions and make corresponding responses;\n8. Without diseases that severely affect cognitive and motor functions, including cardiovascular diseases (such as uncontrolled hypertension, heart failure, etc.), neurological diseases (such as Parkinson's disease, stroke, epilepsy, etc.), musculoskeletal diseases (such as severe arthritis, recent fractures, etc.), etc.;\n9. Normal vision and hearing or corrected to normal, without affecting the understanding of instructions and participation in interventions;\n10. Conscious and able to understand the test requirements;\n11. Able to understand and sign the informed consent form voluntarily, and willing to cooperate in completing the research procedures.\n\nExclusion Criteria:\n\n1. Must rely on assistive walking devices or others to walk;\n2. Individuals with color vision disorders, including various types of color blindness and color weakness;\n3. Unable to correctly perform addition and subtraction operations;\n4. Those allergic to the materials of research equipment;\n5. Currently participating in other research or intervention projects that may affect the effectiveness of this intervention.",true,"ALL","65 Years",{"count":20,"type":21},125,"ESTIMATED","INTERVENTIONAL",[24],"NA","1. Develop an evidence-based dual-task intervention programme incorporating gamification for fall risk reduction in older adults.\n2. Examine the effects of the gamified dual-task intervention on fall risk in older adults.\n3. Elucidate the underlying mechanisms of the optimal gamified dual-task intervention programme in reducing falls in older adults.",[27,28,29,30],"ELDERLY PEOPLE","Cognitive-motor Dual-task","Fall Prevention","Intervention","NOT_YET_RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":21},"2027-03-31",{"date":37,"type":21},{"name":40,"class":41},"Jinyao Wang","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100583764","seniors-integrated-longitudinal-cardiovascular-evaluation-of-coronary-heart-disease-a-multicenter-prospective-registry-in-china-silver-china-100583764","NCT06880575","Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)","SILVER-China","Inclusion Criteria:\n\n① Age requirements: Participants are ≥ 75 years old;\n\n* This time he was admitted to the hospital due to angina pectoris and other coronary heart disease-related symptoms\n\n  ③ Conform to the diagnosis of coronary heart disease: meet any one of the following conditions:\n  1. This admission was performed for coronary angiography, coronary artery CTA confirmed coronary heart disease;\n  2. Previous clear coronary angiography, coronary artery Coronary heart disease diagnosed by imaging evidence such as CTA evidence;\n  3. The attending physician according to the patient's symptoms, medical history, myocardial injury markers, electrocardiogram, echo cardiography, myocardial radionuclide imaging, etc. diagnosed coronary heart disease.\n\n     ④ Informed consent: Participants must be able to understand the content of the study, voluntarily participate in the study, and sign the informed consent form.\n\n     Exclusion Criteria:\n     * Combined with severe non-cardiovascular disease: life expectancy does not exceed 6 months, such as advanced cancer or other end-stage disease;\n* Unable to cooperate with long-term follow-up: such as patients with severe cognitive impairment or severe mental illness; ③ Non-cardiogenic death within 24 hours after admission.","75 Years",{"count":51,"type":21},10139,"5 Years","OBSERVATIONAL","This study aims to establish a nationwide cohort and biobank of elderly patients with coronary heart disease (CHD) and to develop risk prediction models and clinical treatment optimization plans based on this data. The specific research content is as follows:\n\nThe Study plan to continuously enroll hospitalized elderly CHD patients across 50 centers nationwide. Using networked electronic data collection technology, standardized methods and protocols will be used to gather demographic information (such as age, gender, education level, income, etc.), clinical information (medical history, past treatment records, current treatment plans, surgical records, medication use, etc.), lifestyle information (dietary habits, exercise frequency, smoking, drinking, etc.), biological information (such as inflammatory markers, etc.), and physical examination data (such as blood pressure, ECG, sleep monitoring, imaging examinations, etc.). These patients will be followed up long-term (1 month, 6 months, 1 year, and annually thereafter for up to 5 years) to establish a database that meets international standards. Centers meeting the criteria will also retain biological samples, creating a multicenter biobank for elderly CHD patients.\n\nSecond, based on the established clinical cohort, a risk prediction model for elderly CHD patients will be developed, including mortality risk, ischemic risk, bleeding risk, etc. Additionally, optimized clinical diagnostic and treatment plans will be formulated to improve the treatment outcomes and quality of life for elderly CHD patients. This research is expected to provide scientific evidence and technical support for the prevention, diagnosis, and treatment of CHD in elderly patients.",[56,27],"Coronary Arterial Disease (CAD)",[58,59,60],"Coronary Heart Disease","Chinese Elderly","Cohort Study","RECRUITING","2025-03-14",{"date":64,"type":35},"2025-03-17",{"date":66,"type":35},"2024-11-06",{"date":68,"type":21},"2027-06-30",{"name":70,"class":71},"Beijing Hospital","OTHER_GOV",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100579508","etoposide-plus-benmelstobart-followed-by-maintenance-therapy-of-benmelstobart-plus-anlotinib-in-first-line-treatment-of-elderly-patients-with-extensive-stage-small-cell-lung-cancer-a-single-arm-prospective-trial-100579508","NCT06825208","Etoposide Plus Benmelstobart Followed by Maintenance Therapy of Benmelstobart Plus Anlotinib in First-line Treatment of Elderly Patients with Extensive Stage Small Cell Lung Cancer: a Single-arm, Prospective Trial","Inclusion Criteria:\n\n* Patients with pathologically proven extensive small-cell Lung cancer (according to the Veterans Administration Lung Study Group, VALG stage) who have not previously received systematic treatment for extensive small-cell lung cancer;\n* Patients who have previously received chemoradiotherapy for limited-stage SCLC must have received radical therapy and have at least 6 months of treatment-free intervals between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive SCLC (end time of last chemotherapy cycle\u002Fend time of last radiotherapy).\n* There was no gender limitation. The subjects voluntarily joined the study, signed the informed consent, and the compliance was good\n* Aged eligibility criteria are considered to be met if the following criteria are met:\n\nPatient requirements: Between 70 and 85 years old, and after independent assessment by two chief physicians, the patient's physical condition may not be able to tolerate platinum-containing chemotherapy regimen, and the patient's informed consent to accept the platinum treatment regimen;\n\n* ECOG score: 0-2;\n* At least one lesion can be measured by CT.\n* Expect to survive for at least 3 months.\n* The main organ functions within 7 days before treatment should meet the following criteria:\n\n  1\\) Blood routine examination (under the condition of no blood transfusion or use of hematopoietic stimulating factor drugs for correction within 14 days): Hemoglobin (Hb) ≥ 90g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL; ； 1) Platelet count (PLT) ≥ 100×10⁹\u002FL; white blood cell count (WBC) ≥ 3.0×10⁹\u002FL.\n\n  2\\) Biochemical tests: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (for patients with liver metastasis from tumors, ≤ 5×ULN); total bilirubin (TBIL) ≤ 1.5×ULN (for Gilbert's syndrome patients, ≤ 3×ULN); serum creatinine (Cr) ≤ 1.5×ULN or creatinine clearance rate ≥ 50 ml\u002Fmin; 3) Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN; 4) Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ 50%. 。\n* Men should agree that contraception must be used during the study period and for 6 months after the end of the study period;\n\nExclusion Criteria:\n\n* Used antiangiogenic drugs or related immunotherapy drugs such as PD-1 and PD-L1 in the past;\n* Subjects with known central nervous system metastatic and\u002For cancerous meningitis; (Unless asymptomatic, or treated and stable, no radiographic evidence of new BMS or enlarged BMS was found at least 2 weeks after BMS treatment, and steroid or anticonvulsant therapy was discontinued for at least 14 days before study therapy began. If active or new untreated, asymptomatic CNS metastases are found on imaging in subjects during the screening period, radiation therapy or untreated imaging evidence of new or enlarged BMS is required for at least 2 weeks.)\n* Subject has had or co-developed other malignancies (except cured basal cell carcinoma of the skin and cervical carcinoma in situ) within 5 years;\n* Subject has multiple factors that affect oral medication (such as inability to swallow, post-gastrointestinal resection, chronic diarrhea, and intestinal obstruction);\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n* Spinal cord compression that has not been cured or alleviated by surgery and\u002For radiotherapy, or previously diagnosed spinal cord compression with no clinical evidence of disease stabilization ≥1 week prior to randomization after treatment;\n* Imaging (CT or MRI) shows that the tumor invades the large blood vessels or has an unclear boundary with the large blood vessels;\n* Subjects with evidence or history of bleeding tendencies, regardless of severity, within 2 months prior to initial dosing; A history of hemoptysis (defined as bright red or 1\u002F2 teaspoon of blood) or unhealed wounds, ulcers, or fractures within 2 weeks prior to initial medication;\n* Subjects whose adverse events (other than alopecia) from prior treatment did not recover to ≤CTCAE Class 1;\n* Received major surgical treatment or significant traumatic injury within 28 days prior to randomization;\n* Those who had experienced an arterial\u002Fvenous thrombosis event, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism, within 6 months before randomization;\n* have a history of psychotropic drug abuse and can not quit or have mental disorders;\n* Subjects with any severe and\u002For uncontrolled medical condition, including:\n\n  a) Subjects with unsatisfactory blood pressure control (systolic ≥150 mmHg or diastolic ≥100mmHg); b) have grade 2 myocardial ischemia or myocardial infarction, arrhythmias (including QTc≥450ms in men, QTc≥ 470ms in women), and grade 2 congestive heart failure (NYHA); c) Active or uncontrolled severe infection (≥CTC AE grade 2 infection); d) Cirrhosis, active hepatitis \\*;\n\n  \\* Active hepatitis (Hepatitis B reference :HBsAg positive, and HBV DNA test value exceeds the upper limit of normal; Hepatitis C reference :HCV antibody positive, and HCV virus titer test value exceeds the upper limit of normal value); e) HIV positive test; f) Poor diabetes control (fasting blood glucose (FBG)\\>10mmol\u002FL); g) Urine routine indicated urine protein ≥++, and confirmed 24-hour urine protein quantity \\>1.0 g;\n* have received prophylactic or attenuated vaccine within 4 weeks before the first dose;\n* Severe hypersensitivity after administration of other monoclonal antibodies;\n* The need for systemic treatment (e.g., use of disease-modifying drugs, Active autoimmune diseases with corticosteroids or immunosuppressants (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; Patients with asthma requiring medical intervention with bronchodilators were not included). Replacement therapies (such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic.\n* have been diagnosed with an immune deficiency or are receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy (dose \\>10mg\u002F day prednisone or other therapeutic hormone) and continue to use within 2 weeks before the first dose;\n* Have participated in other clinical trials within four weeks;\n* concomitant diseases that, in the investigator's judgment, seriously endanger the safety of the subject or interfere with the patient's completion of the study.","70 Years","85 Years",{"count":82,"type":21},29,"This is a prospective, single-arm clinical study to evaluate the efficacy and safety of etoposide in combination with bemosubezumab and sequential Benmelstobart in combination with Anlotinib as first-line treatment for elderly patients with extensive small-cell lung cancer.\n\nParticipants who met the inclusion criteria were selected to enter the study and received etoposide combined with Benmelstobart followed by bemosubezumab combined with Anlotinib. The primary endpoint was PFS (Progression-free Survival), the secondary endpoint was OS (Overall Survival) and safety (CTCAE 5.0), and the exploratory endpoint was the screening of various potential molecular markers.",[85,27],"Small Cell Lung Cancer Extensive Stage","2025-02-09",{"date":88,"type":35},"2025-02-13",{"date":90,"type":21},"2025-02",{"date":92,"type":21},"2027-06",{"name":94,"class":41},"Nanjing First Hospital, Nanjing Medical University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":72},"100579248","the-efficacy-of-modified-olfactory-training-for-mci-high-risk-individuals-100579248","NCT06821828","The Efficacy of Modified Olfactory Training for MCI High-Risk Individuals","Assessing Modified Olfactory Training to Prevent Cognitive Decline in MCI High-Risk Individuals: A Randomized Controlled Trial Protocol","Inclusion Criteria:\n\n1. Age and Gender: Individuals aged 60-80 years, regardless of gender.\n2. Diagnosis of Idiopathic Olfactory Dysfunction: overall TDI score below 30.75 points using the Sniffin' Sticks test. Without olfactory impairment due to traumatic, sinusitis-related, congenital, toxic\u002Fdrug-induced causes, post-operative conditions, tumors, or post-upper respiratory infections.\n3. Diagnosis of Subjective Cognitive Decline: Montreal Cognitive Assessment (MoCA) score \\>24 for middle school level and above, \\>19 for elementary school level, and \\>13 for illiterate individuals. Amyloid β (Aβ) deposition in the brain (defined as Aβ42 \\\u003C 550 ∼ 813 pg\u002Fml)， the higher Formula of Hulstaert (defined as \\[(Aβ42\u002F(240 + 1.18 × tau) ≤1\\]）, and hippocampus atrophy.\n4. Consent: Willingness to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Comorbid Chronic Diseases or Severe Concurrent Illnesses: Individuals with conditions such as hypertension, diabetes, bronchopneumonia, malignant tumors， or chronic obstructive pulmonary disease.\n\n4\\. Recent Medication Use: Exclusion of participants who have taken corticosteroids, antimicrobials, leukotriene antagonists, or antihistamines within the last four weeks.\n\n5\\. Inability to Comply with Study Requirements: Based on the researcher's judgment, individuals who are unable to tolerate olfactory function tests and treatment， complete the study or comply with its requirements due to memory or behavioral abnormalities, depression, severe alcohol consumption, or previous non-compliance.","60 Years","90 Years",{"count":105,"type":21},114,[24],"The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are: Is it possible that the device can delay the progression of MCI in older adults? Compared to the conventional device, how efficient is the modified olfactory training device for improving cognitive function?",[109,110,111,27],"Subjective Cognitive Decline (SCD)","Olfactory Dysfunction","Mild Cognitive Impairment (MCI)",[111,109,113,114,110],"olfactory training","elderly population","2025-02-06",{"date":117,"type":35},"2025-02-12",{"date":119,"type":21},"2025-03-22",{"date":121,"type":21},"2027-05-22",{"name":123,"class":41},"Peking University Third Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":16,"sex":17,"minAge":102,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":72},"100568784","laughter-yoga-is-role-in-enhancing-sleep-and-well-being-in-the-elderly-100568784","NCT06685731","Laughter Yoga is Role in Enhancing Sleep and Well-being in the Elderly","The Effects of Laughter Yoga on Sleep Quality, Vitality, Active Aging, and Quality of Life in Elderly Individuals","Inclusion Criteria:\n\n* Reside in Şavşat,\n* Aged 60 or over,\n* No issues with vision, hearing, or perception,\n* Scored 24 or higher on the Mini-Mental State Examination,\n* Not undergoing psychiatric treatment,\n* No physical limitations that would impede participation in laughter yoga (e.g., fractures, open wounds, or muscle weakness in the hands, wrists, or arms),\n* Literate,\n* Open to communication,\n* Willing to participate in the study.\n\nExclusion Criteria:\n\n* Scored below 24 on the Mini-Mental State Examination,\n* Severe hearing or perceptual impairments that hinder communication,\n* Major psychiatric disorders,\n* Underwent surgery within the last three months,\n* Medical conditions that could cause physical strain or increase abdominal pressure during laughter yoga (e.g., bleeding hemorrhoids, any type of hernia, persistent cough, severe back pain, heart disease, hypertension, urinary incontinence, epilepsy), and individuals with oncological conditions will be excluded from the study.",{"count":132,"type":21},60,[24],"Objective:\n\nThe study aims to evaluate the effects of Laughter Yoga on sleep quality, vitality, active aging, and quality of life in individuals aged 60 and over.\n\nMethod:\n\nThis randomized controlled experimental study will be conducted between 01.09.2024 and 31.12.2024 with elderly individuals aged 60 and over who are registered at Şavşat Family Health Center No. 1. The study population consists of 6,797 individuals. Participants will be randomly assigned to an experimental group (30) and a control group (30) using a simple randomization method. Data will be collected using a Personal Information Form, Mini-Mental State Examination, Active Aging Scale, Pittsburgh Sleep Quality Index, Subjective Vitality Scale, and Quality of Life Scale for the Elderly. The experimental group will participate in 12 Laughter Yoga sessions, conducted twice a week for 6 weeks, with each session lasting 40 minutes. No intervention will be applied to the control group. At the end of the 6th week, final measurements will be taken from both groups at the family health center.",[27],[137,138,139,140,141,142],"elderly","Laughter Yoga","Sleep Quality","Vitality","Active Aging","Elderly Quality of Life","2024-11-11",{"date":145,"type":35},"2024-11-12",{"date":147,"type":35},"2024-09-05",{"date":149,"type":21},"2024-12-31",{"name":151,"class":41},"Artvin Coruh University"]